{"id":670639,"date":"2026-05-28T19:03:12","date_gmt":"2026-05-28T19:03:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/670639\/"},"modified":"2026-05-28T19:03:12","modified_gmt":"2026-05-28T19:03:12","slug":"syncell-discovery-services-launches-powered-by-proprietary-platform","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/670639\/","title":{"rendered":"Syncell Discovery Services Launches, Powered by Proprietary Platform"},"content":{"rendered":"<p class=\"has-background\" style=\"background-color:#bebebe\">Editor\u2019s Take: Drug target discovery, biomarker identification, and disease biology research are increasingly demanding higher-resolution tools and services.<\/p>\n<p><a href=\"https:\/\/www.syncell.com\" rel=\"nofollow noopener\" target=\"_blank\">Syncell<\/a> is commercially launching Syncell Discovery Services, a global sample-to-discovery program delivering insights from the company\u2019s proprietary Microscoop Mint platform.<\/p>\n<p>Specializing in next-generation proteomics analysis, Syncell aims to provide biopharma, translational research organizations, and academic institutions direct access to results. The Microscoop Mint platform promises\u00a0in situ proteome coverage and precision, surpassing limits of traditional approaches to protein analysis.<\/p>\n<p>Syncell Gives Reasons for Program Launch<\/p>\n<p>Syncell Chief Commercial Officer Nikhil Rao, PhD, suggests demand is rising for higher-resolution tools in a few distinct areas. These include biomarker identification, drug target discovery, and disease biology research.<\/p>\n<p>\u201cToday\u2019s technology is unable to discover novel biomarkers at the site-specific, subcellular locations where disease actually unfolds,\u201d Rao said. \u201cThat gap matters.\u201d<\/p>\n<p class=\"has-text-align-center has-vivid-red-color has-text-color has-link-color wp-elements-323f82efe90719400260456540784794\">\u201cDuring the pilot phase, demand quickly outpaced capacity, with customers identifying proteins not previously known to be at their site of interest.\u201d<\/p>\n<p class=\"has-text-align-center\">Nikhil Rao, PhD, Chief Commercial Officer, Syncell<\/p>\n<p>Neuroscience, oncology and, broadly, drug discovery, have just one or two known biomarkers per indication, Rao says. Accordingly, this leaves the next generation of targets \u201chidden in plain sight.\u201d<\/p>\n<p>The pilot phase of Syncell Discovery Services, however, changed this perception, Rao revealed.<\/p>\n<p>\u201cDemand quickly outpaced capacity, with customers identifying proteins not previously known to be at their site of interest,\u201d Rao said. \u201cThat traction has also translated into growing pharma interest in the Microscoop Mint platform itself.\u201d<\/p>\n<p>How Discovery Services Will Integrate<\/p>\n<p>Syncell claims that Discovery Services\u2019 highly precise subcellular workflow can uncover protein biology features that are normally inaccessible. And this is true among multiple approaches\u2014conventional spatial proteomics, laser capture, and proximity labeling.<\/p>\n<p>The program, the company says, delivers a unique path to unbiased nanoscopic proteomic insights. Also, the Microscoop Mint platform can be integrated with, for example, <a href=\"https:\/\/www.contractpharma.com\/company-profile\/thermo-fisher-scientific-pharma-services\/\" rel=\"nofollow noopener\" target=\"_blank\">Thermo Fisher Scientific<\/a>\u2019s Orbitrap Astral mass spectrometer series.<\/p>\n<p>Following the pilot phase, demand for Syncell Discovery Services is oversubscribed at launch, according to the company. Syncell says it is working to expand its service provider network worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"Editor\u2019s Take: Drug target discovery, biomarker identification, and disease biology research are increasingly demanding higher-resolution tools and services.&hellip;\n","protected":false},"author":2,"featured_media":670640,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-670639","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/670639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=670639"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/670639\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/670640"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=670639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=670639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=670639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}